GSK plc (GSK) SEC Filings & Financial Intelligence
GSK plc (GSK) is a publicly traded company on the NYSE, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: GSK
CIK: 1131399
Exchange: NYSE
SIC 2834: Pharmaceutical Preparations
State: X0
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Deloitte LLP
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerKate Houldsworth
Audit LocationLondon, United Kingdom
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 6-K | 2026-11-06 | 2026-11-06 | GSK PUBLISHES PROVISIONAL DIVIDEND DATES | 0001654954-26-009585 | View SEC Doc Filr Page |
| 13F-HR | 2026-11-05 | 2026-09-30 | 13F-HR Filing | 0001999371-26-024635 | View SEC Doc Filr Page |
| 6-K | 2026-11-02 | 2026-11-02 | TOTAL VOTING RIGHTS | 0001654954-26-009362 | View SEC Doc Filr Page |
| 6-K | 2026-10-28 | 2026-10-28 | 3RD QUARTER RESULTS | 0001654954-26-009181 | View SEC Doc Filr Page |
| 6-K | 2026-10-26 | 2026-10-26 | RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA | 0001654954-26-009141 | View SEC Doc Filr Page |
| 6-K | 2026-10-26 | 2026-10-26 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-009139 | View SEC Doc Filr Page |
| 6-K | 2026-10-26 | 2026-10-26 | JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE | 0001654954-26-009130 | View SEC Doc Filr Page |
| 6-K | 2026-10-26 | 2026-10-26 | POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER | 0001654954-26-009127 | View SEC Doc Filr Page |
| 6-K | 2026-10-21 | 2026-10-21 | US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B | 0001654954-26-009062 | View SEC Doc Filr Page |
| 6-K | 2026-10-19 | 2026-10-19 | JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER | 0001654954-26-009036 | View SEC Doc Filr Page |
| 6-K | 2026-10-19 | 2026-10-19 | RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER | 0001654954-26-009023 | View SEC Doc Filr Page |
| 6-K | 2026-10-15 | 2026-10-15 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008959 | View SEC Doc Filr Page |
| 6-K | 2026-10-14 | 2026-10-14 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008950 | View SEC Doc Filr Page |
| S-8 | 2026-10-13 | — | S-8 | 0001193125-26-420025 | View SEC Doc Filr Page |
| 6-K | 2026-10-13 | 2026-10-13 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008921 | View SEC Doc Filr Page |
| 6-K | 2026-10-13 | 2026-10-13 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008889 | View SEC Doc Filr Page |
| 6-K | 2026-10-08 | 2026-10-08 | WENDY BECKER CBE - NEW DIRECTORSHIP | 0001654954-26-008854 | View SEC Doc Filr Page |
| 6-K | 2026-10-06 | 2026-10-06 | ADMISSION TO TRADING | 0001654954-26-008813 | View SEC Doc Filr Page |
| 6-K | 2026-10-01 | 2026-10-01 | TOTAL VOTING RIGHTS | 0001654954-26-008733 | View SEC Doc Filr Page |
| 6-K | 2026-09-24 | 2026-09-24 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008553 | View SEC Doc Filr Page |
| CERT | 2026-09-22 | — | NYSE CERTIFICATION | 0000876661-26-000783 | View SEC Doc Filr Page |
| 6-K | 2026-09-22 | 2026-09-22 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008503 | View SEC Doc Filr Page |
| 8-A12B | 2026-09-15 | — | 8-A12B | 0001193125-26-391619 | View SEC Doc Filr Page |
| 6-K | 2026-09-15 | 2026-09-15 | 6-K | 0001193125-26-391597 | View SEC Doc Filr Page |
| 6-K | 2026-09-15 | 2026-09-15 | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA | 0001654954-26-008359 | View SEC Doc Filr Page |